A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505057-40-00

Acronym

213824

Enrollment

174

Registered

2024-06-11

Start date

2022-12-02

Completion date

Unknown

Last updated

2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Non-Small Cell

Brief summary

Incidence of TEAEs and SAEs Incidence of TEAEs/SAEs leading to dose modifications (e.g., dose delay) or study intervention discontinuation

Interventions

DRUGJEMPERLI 500 mg concentrate for solution for infusion

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of TEAEs and SAEs Incidence of TEAEs/SAEs leading to dose modifications (e.g., dose delay) or study intervention discontinuation	—

Countries

Belgium, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026